证券代码：603301 证券简称：振德医疗 振德医疗用品股份有限公司 2023 年第一季度报告 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 (一)公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 (二)公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 (三)第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (四)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度(%) | | | --- | --- | --- | --- | | 营业收入 | 1,300,476,798.62 | | 2.82 | | 归属于上市公司股东的净利润 | 146,461,478.20 | | 30.92 | | 归属于上市公司股东的扣除非经常性 损益的净利润 | 140,905,8 ...

证券代码：603301 证券简称：振德医疗 公告编号：2023-015 振德医疗用品股份有限公司关于 召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2023 年 5 月 9 日（星期二）10:00-11:00 2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2023 年 4 月 27 日（星期四） 至 5 月 8 日（星 期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明 会上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布公司 2022 年度报告以及 2023 年第一季度报告。为便于 广大投资者更全面深入地了解公司2022 年度和2023 年一季度经营成 果、财 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：603301 证券简称：振德医疗 振德医疗用品股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|------------------------------|------------------|---------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥2,767,031,431.20, a decrease of 4.98% compared to ¥2,912,105,568.85 in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2022 was ¥271,574,153.43, down 28.19% from ¥378,203,869.98 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥283,036,443.39, a decrease of 16.41% compared to ¥338,605,771.21 in the same period last year[22]. - The net cash flow from operating activities was ¥85,271,465.41, a significant decline of 74.84% from ¥338,953,666.48 in the previous year[22]. - Basic earnings per share for the first half of 2022 were ¥1.21, down 27.11% from ¥1.66 in the same period last year[25]. - The diluted earnings per share were ¥1.20, a decrease of 27.71% compared to ¥1.66 in the previous year[25]. - The weighted average return on net assets was 6.52%, a decrease of 2.31 percentage points from 8.83% in the previous year[25]. - The company's revenue for Q2 2022 was 1.502 billion RMB, an increase of 18.77% compared to Q1 2022[26]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, for Q2 2022 was 183 million RMB, up 82.82% from Q1 2022[26]. - The net profit attributable to the parent company for Q2 2022 was 160 million RMB, an increase of 42.75% compared to Q1 2022[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,125,746,328.34, an increase of 10.96% from ¥6,421,676,690.51 at the end of the previous year[22]. - The net assets attributable to shareholders at the end of the reporting period were ¥4,198,276,902.97, up 3.23% from ¥4,066,740,693.18 at the end of the previous year[22]. - Total liabilities reached RMB 2,732,328,057.94, compared to RMB 1,982,076,740.76, indicating a rise of 37.8%[177]. - Short-term borrowings increased to RMB 904,879,124.47, compared to RMB 660,725,916.67, a growth of 36.8%[175]. - Long-term borrowings rose to RMB 525,505,138.89, compared to RMB 145,155,069.44, representing an increase of 262.5%[175]. Market Position and Strategy - The company has established a marketing network covering over 6,300 hospitals across China, including more than 950 top-tier hospitals[31]. - The company ranks among the top three in China's medical dressing exports for several consecutive years[31]. - The company focuses on medical-grade personal care and family health care products, with a wide range of offerings[31]. - The company has developed efficient business cooperation systems with many well-known foreign medical device brands[31]. - The company’s products are recognized in over 70 countries and regions worldwide, including Europe, North America, and Asia[31]. - The company achieved a nationwide coverage rate of 97% in top 100 chain pharmacies, reaching over 100,000 pharmacy stores and more than 15,000 supermarkets and convenience stores[34]. - The company operates over 10 online stores on platforms like Tmall, JD.com, and Pinduoduo, with a total fan base exceeding 6 million[34]. - The company is focused on expanding its market presence both online and offline, leveraging its brand influence[34]. Research and Development - Research and development expenses increased by 32.99% to ¥98,734,445.53, reflecting the company's commitment to innovation and product development[76]. - The company is focusing on R&D investments, enhancing material analysis capabilities, and developing new products to meet clinical needs, including antimicrobial dressings[69]. - The company has established an independent marketing team for modern wound care products and set up a marketing team overseas to enhance market share[67]. Risks and Challenges - The company faces risks from regulatory changes in the healthcare sector, which could impact operations if not adapted to new policies[5]. - Product quality risks are significant due to the nature of medical supplies, necessitating strict quality control measures to maintain safety and reliability[5]. - Market risks include increased competition in both domestic and international markets, particularly from lower-cost regions[5]. - The company is enhancing its supply chain and quality management systems to mitigate risks associated with product quality and market competition[5]. Corporate Governance and Commitments - The company elected new board members including Wang Jiafen, Ni Ya, Li Shengxiao, and Zhu Chafen as independent directors[101]. - The company did not distribute profits or increase capital reserves, with no dividends or stock bonuses declared[105]. - The company has committed to a gradual reduction plan post-lock-up, limiting annual sales to no more than 5% of the total shares outstanding at the end of the previous year[121]. - The company will ensure that any profits gained from non-compliance with commitments will be returned to the company within five working days[124]. - The company has established measures to extend the lock-up period by three months if any commitments are violated[121]. Environmental and Social Responsibility - The company has not faced any environmental penalties and emphasizes green development and compliance with environmental regulations[112]. - The company has established an ISO system for environmental management and promotes energy-saving and emission-reduction initiatives[115]. - The company has implemented measures to enhance employee environmental awareness and increase investment in environmental protection[115].

Financial Performance - The company's operating revenue for 2021 was ¥5,091,572,447.78, a decrease of 51.04% compared to ¥10,398,545,638.73 in 2020[23]. - Net profit attributable to shareholders was ¥595,861,926.07, down 76.63% from ¥2,549,453,200.21 in the previous year[23]. - The net cash flow from operating activities decreased by 73.80% to ¥817,629,318.83 from ¥3,120,839,894.43 in 2020[23]. - Basic earnings per share fell to ¥2.64, a decline of 78.88% compared to ¥12.50 in 2020[23]. - The weighted average return on equity decreased to 14.22%, down 80.66 percentage points from 94.88% in 2020[23]. - The decline in revenue was primarily due to a decrease in sales of pandemic-related protective products as the domestic pandemic was effectively controlled[24]. - The gross profit margin was negatively impacted by global freight capacity shortages, exchange rate fluctuations, and rising raw material prices[26]. - The company achieved a total revenue of 4.907 billion RMB, a decrease of 52.41% year-on-year, but an increase of 164.43% compared to 2019[35]. - Revenue from epidemic prevention products reached 1.669 billion RMB, while excluding these products, the revenue was 3.238 billion RMB, reflecting a year-on-year growth of 17.87%[35]. - The net profit attributable to the parent company was 596 million RMB, down 76.63% year-on-year, but up 279.80% compared to 2019[35]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares, totaling 136,322,841.60 CNY (including tax) for the 2021 fiscal year[6]. - The company’s total unallocated profits will be carried forward to the next fiscal year after the dividend distribution[6]. - The company has committed to a three-year shareholder return plan for 2021-2023, emphasizing its focus on shareholder value[177]. - The total number of shares held by directors and senior management decreased from 10,864,525 at the beginning of the year to 10,567,525 at the end of the year, a reduction of 297,000 shares[180]. - The total pre-tax remuneration for directors and senior management during the reporting period amounted to 1,069.82 million yuan[180]. Corporate Governance and Compliance - The company reported a standard unqualified audit opinion from Tianjian Accounting Firm for the fiscal year 2021[5]. - The company’s board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[4]. - The company has established a comprehensive internal control system to enhance corporate governance and risk management capabilities[172]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with all shareholders[172]. - The audit committee, nomination committee, and compensation committee are all chaired by independent directors, ensuring a majority of independent oversight[173]. Risk Management - The company has detailed potential risks in the report, which can be found in the section discussing future development[8]. - The company’s future plans and strategic developments are subject to investment risks, as stated in the forward-looking statements[7]. - The company faces risks related to regulatory changes in the healthcare industry, which could impact its operations if it fails to adapt to new policies[162]. - The company is experiencing increased competition in the medical dressing export market due to geopolitical uncertainties and rising domestic labor costs[165]. - The company is actively managing risks associated with fluctuations in exchange rates, raw material prices, and shipping costs through strategic pricing mechanisms and forward contracts[165]. Research and Development - The company invested in various information technology systems to enhance operational efficiency and support business development[43]. - The company is committed to increasing its research and development investment, focusing on surgical infection control materials and ostomy wound care technologies[153]. - The company has established a quality management system certified by ISO13485 and has passed multiple inspections by the FDA and local drug regulatory authorities, ensuring product quality[74]. - The company holds 51 invention patents and 486 utility model patents, along with 93 Class II and 9 Class III medical device registrations, enhancing its innovation capabilities[74]. - The company is focused on continuous innovation in product design and technology to meet the evolving needs of the healthcare market[64]. Market Expansion and Strategy - The company aims to become a leading healthcare enterprise with a target of reaching a market value of 100 billion RMB through a multi-channel marketing strategy focused on "medical + health"[146]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[186]. - The company plans to enhance its digital marketing efforts, aiming for a 50% increase in online sales[186]. - The company is actively pursuing market expansion through acquisitions, as evidenced by the acquisition of Anhui Lanxin and Shanghai Yao, which has broadened its product portfolio[122]. - The company plans to strengthen its regulatory compliance and monitoring mechanisms to ensure product quality and safety throughout the product lifecycle[122]. Operational Efficiency - The company implemented significant organizational and talent development initiatives to support rapid growth and improve operational efficiency[41]. - The company achieved a gross margin improved to 45%, up from 40% in the previous year, indicating better cost management[186]. - The company aims to improve production efficiency and product quality through lean management practices and automation upgrades[158]. - The company has emphasized lean manufacturing and has optimized its production processes, leading to improved supply chain efficiency and cost reduction[74]. - The company plans to enhance its digital infrastructure, including the completion of the second phase of its CRM system to improve operational management capabilities[154]. Acquisitions and Investments - The company acquired 100% equity of Shanghai Yaoao and Nantong Zhend, and increased its stake in Anhui Lanxin to 60% during the reporting period[96]. - The company approved an investment of approximately CNY 650 million for the construction of a new medical device production base and research institute in Shaoxing, Zhejiang Province, with land acquisition costs of CNY 45.13 million for 66,852 square meters[137]. - The company is in the process of expanding its surgical infection control production line with a total investment of CNY 845 million, which is currently under construction[137]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[186]. - The company has proposed a non-public issuance of A-shares for 2021, with a feasibility analysis report on the use of raised funds[198].

Financial Performance - Revenue for Q3 2021 was CNY 950,542,476.87, a decrease of 77.88% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2021 was CNY 104,325,942.71, down 90.59% year-on-year[7] - Basic earnings per share for Q3 2021 was CNY 0.46, a decline of 91.40% compared to the previous year[9] - Revenue for the year-to-date period was CNY 3,862,648,045.72, down 52.41% year-on-year[7] - Net profit attributable to shareholders for the year-to-date period was CNY 482,529,812.69, a decrease of 77.00% compared to the previous year[7] - Total operating revenue for the first three quarters of 2021 was CNY 3,862,648,045.72, a decrease from CNY 8,116,660,488.11 in the same period of 2020, representing a decline of approximately 52.3%[26] - Net profit for the first three quarters of 2021 was CNY 585,594,652.61, compared to CNY 2,409,971,170.87 in 2020, reflecting a decrease of approximately 75.7%[33] - The total comprehensive income attributable to the parent company for the first three quarters of 2021 is CNY 482,529,812.69, compared to CNY 2,097,753,320.69 in the same period of 2020, indicating a significant decrease[35] Assets and Liabilities - Total assets as of the end of Q3 2021 were CNY 6,782,938,953.56, an increase of 5.98% from the end of the previous year[9] - The company's total assets as of September 30, 2021, are approximately ¥6.78 billion, compared to ¥6.40 billion at the end of 2020[24] - The company's total liabilities amounted to CNY 2,465,310,794.24, an increase from CNY 1,933,193,883.17 in the previous year, showing a growth of about 27.5%[26] - The total liabilities increased to approximately ¥2.10 billion from ¥1.74 billion year-over-year[24] - Current liabilities reached approximately $1.74 billion, remaining unchanged from the previous period[47] - Total liabilities were approximately $1.93 billion, down by $62.66 million compared to the previous period[47] Cash Flow - Cash flow from operating activities for the year-to-date period decreased by 80.76% to CNY 514,487,076.18[9] - Net cash flow from operating activities for the first three quarters of 2021 is CNY 514,487,076.18, a decrease from CNY 2,673,731,914.25 in the same period of 2020[39] - Cash inflow from operating activities totaled CNY 4,534,671,652.40 in the first three quarters of 2021, compared to CNY 8,968,332,752.97 in the same period of 2020[39] - The company reported a net increase in cash and cash equivalents of CNY 190,195,182.89 for the first three quarters of 2021, compared to an increase of CNY 1,321,802,813.74 in the same period of 2020[39] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,055[15] - Zhejiang Zhend Medical Holdings Co., Ltd. holds 48.06% of the shares, making it the largest shareholder[15] - The top ten shareholders collectively hold 83.50% of the shares, indicating a high level of concentration[17] - The company has no preferred shareholders with restored voting rights[15] Operational Costs and Expenses - Total operating costs for the first three quarters of 2021 were CNY 3,257,979,534.49, down from CNY 5,206,925,389.74 in 2020, indicating a reduction of about 37.4%[29] - Research and development expenses for the first three quarters of 2021 were CNY 105,536,290.91, compared to CNY 166,626,599.77 in 2020, a reduction of about 36.6%[29] - The company reported a profit from operations of CNY 668,686,550.96, significantly lower than CNY 2,899,823,827.82 in the same period of 2020, a decline of approximately 77.0%[31] - The company’s financial expenses decreased to CNY 5,716,071.15 from CNY 48,082,599.43, a reduction of approximately 88.1%[29] Market Conditions - The decline in revenue and profit was attributed to the normalization of prices for pandemic-related protective products and increased shipping costs due to global supply chain issues[11] Other Financial Metrics - The weighted average return on equity decreased by 34.76 percentage points to 2.63% in Q3 2021[9] - The company's cash and cash equivalents as of September 30, 2021, amount to approximately ¥1.95 billion, an increase from ¥1.81 billion at the end of 2020[21] - Total current assets decreased to approximately ¥3.73 billion from ¥4.35 billion year-over-year[21] - Short-term borrowings increased to approximately ¥646.84 million from ¥358.37 million year-over-year[24] - The company reported a decrease in inventory to approximately ¥821.55 million from ¥1.08 billion year-over-year[21] - The company’s deferred income tax liabilities increased to CNY 37,619,757.21 from CNY 7,855,497.98, indicating a growth of about 377.5%[26] - The company adopted new leasing standards effective January 1, 2021, impacting the accounting treatment of lease liabilities and right-of-use assets[48]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥2,912,105,568.85, a decrease of 23.76% compared to ¥3,819,840,910.57 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was ¥378,203,869.98, down 61.74% from ¥988,568,649.97 in the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥338,605,771.21, a decrease of 65.60% compared to ¥984,201,245.76 in the same period last year[25]. - The net cash flow from operating activities was ¥338,953,666.48, down 85.11% from ¥2,276,369,995.53 in the previous year[25]. - Basic earnings per share decreased to CNY 1.66, down 67.06% compared to the same period last year[26]. - Diluted earnings per share also fell to CNY 1.66, a decrease of 62.70% year-over-year[26]. - The weighted average return on equity dropped to 8.83%, a decrease of 44.52 percentage points compared to the previous year[26]. - The company achieved a total revenue of 2,907.10 million yuan in the first half of 2021, a decrease of 23.79% compared to the same period last year, but an increase of 284.72% compared to the first half of 2019[50]. - The net profit attributable to the parent company was 378.20 million yuan, down 61.74% year-on-year, but up 529.24% compared to the first half of 2019[50]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,492,339,601.75, an increase of 1.44% compared to ¥6,400,086,700.05 at the end of the previous year[25]. - The net assets attributable to shareholders of the listed company at the end of the reporting period were ¥3,905,266,172.22, a decrease of 6.63% from ¥4,182,785,620.66 at the end of the previous year[25]. - The company's total equity was CNY 4,264,976,257.12, down from CNY 4,466,892,816.88, a decrease of 4.52%[172]. - Total liabilities amounted to CNY 2,227,363,344.63, an increase of 15.23% compared to CNY 1,933,193,883.17 from the previous period[172]. - The company's cash and cash equivalents increased by 25.95% to CNY 2,278,426,000, representing 35.09% of total assets[65]. Sales and Market Strategy - The company has established a marketing network covering over 5,600 hospitals across China, including nearly 900 top-tier hospitals[34]. - The company has over 10 online stores on major e-commerce platforms, with a total fan base exceeding 5 million[34]. - The company focuses on expanding its product lines in both medical and health sectors, including personal care and family health products[34]. - The company is expanding its professional sales and channel teams in the domestic hospital market, aiming to improve sales efficiency and market penetration by over 20%[50]. - The company has achieved a 43.16% year-on-year increase in domestic hospital line sales, reaching 307.74 million yuan, compared to a growth of 81.21% from the first half of 2019[53]. Research and Development - The company is investing in research and development for innovative healthcare solutions, including advanced wound dressings and antiseptic products[39]. - The company has established a comprehensive quality management system certified by ISO13485, enhancing its market competitiveness[46]. - The company launched 4 invention patents and 63 utility model patents during the reporting period, enhancing its technological and competitive edge[56]. - The company reported R&D expenses of CNY 74,240,498.22, slightly up from CNY 73,200,102.13 in the first half of 2020[184]. Risks and Challenges - The company has detailed potential risks in the report, which can be found in the "Management Discussion and Analysis" section[8]. - The company faces risks related to regulatory changes in the medical device industry, which could impact operations if not adapted to timely[81]. - Product quality risks are significant due to the nature of the medical products, and the company is enhancing its quality management systems to mitigate these risks[81]. - The company is exposed to market risks, including increased competition and fluctuating demand for medical products, particularly in the context of global health crises[81]. Strategic Initiatives - The company plans to enhance its market presence through strategic partnerships and potential acquisitions in the healthcare sector[39]. - The company approved a share repurchase plan with a total fund of no less than RMB 120 million and no more than RMB 160 million, with a maximum repurchase price of RMB 90 per share[84]. - The company plans to acquire 30% of Suzhou Medis Medical Sports Goods Co., Ltd. for a total transaction amount of RMB 87 million, which will make Medis a wholly-owned subsidiary[84]. - The company aims to enhance its brand image through a new logo and digital marketing strategies, focusing on consumer interaction and brand loyalty[56]. Environmental and Compliance Commitments - The company emphasized its commitment to environmental protection and green development during its operations[100]. - The company committed to strict adherence to pre-IPO promises, including timely disclosure of any failures to fulfill commitments and compensation for investor losses[111]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[100].

Dividend and Share Capital - The company plans to distribute a cash dividend of 23.00 CNY per 10 shares (including tax), totaling approximately 517.74 million CNY based on 225,104,736 shares after excluding repurchased shares[8]. - The company reported a total share capital of 227,204,736 shares as of the report date, with 2,100,000 shares held in the repurchase account not participating in the dividend distribution[8]. - The company's net profit attributable to ordinary shareholders for 2020 was RMB 2,549,453,200.21, with a dividend payout ratio of 20.31%[179]. - The cash dividend policy aims to provide continuous and stable cash dividends while ensuring the company's operational growth[176]. - The company completed its share repurchase ahead of schedule due to business needs and operational conditions[174]. - The company repurchased a total of 2,100,000 shares, accounting for 0.92% of the total share capital, with a total transaction amount of RMB 133,344,319.82[174]. Financial Performance - The company's operating revenue for 2020 reached ¥10,398,545,638.73, a significant increase of 456.75% compared to ¥1,867,727,915.16 in 2019[29]. - Net profit attributable to shareholders was ¥2,549,453,200.21, up 1,524.99% from ¥156,890,061.60 in the previous year[29]. - The net cash flow from operating activities increased to ¥3,120,839,894.43, representing a growth of 1,478.07% compared to ¥197,762,736.75 in 2019[29]. - Basic earnings per share rose to ¥12.50, a 1,462.50% increase from ¥0.80 in 2019[29]. - The weighted average return on equity increased to 94.88%, up 81.6 percentage points from 13.28% in 2019[29]. - The company's net assets attributable to shareholders grew to ¥4,182,785,620.66, a 207.83% increase from ¥1,358,786,069.59 at the end of 2019[29]. - Total assets increased to ¥6,400,086,700.05, reflecting a growth of 139.77% compared to ¥2,669,238,311.75 in 2019[29]. Risk Management and Compliance - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[10]. - The company has not violated decision-making procedures for external guarantees[10]. - The company has maintained the accuracy and completeness of the annual report as confirmed by its board of directors and management[5]. - The company has not reported any instances of more than half of the directors being unable to guarantee the authenticity of the annual report[10]. - The company emphasizes that forward-looking statements in the report do not constitute a substantive commitment to investors, highlighting potential investment risks[9]. - The company has detailed potential risks in the "Discussion and Analysis of Operating Conditions" section of the report[12]. Market and Sales Strategy - The increase in revenue was primarily driven by a surge in sales of pandemic-related protective products and the consolidation of Rocialle Healthcare Limited's financials following the acquisition of a 55% stake[30]. - The company has established a marketing network covering over 5,300 hospitals in China, including more than 800 top-tier hospitals[43]. - The company has a 95% coverage rate in the top 100 chain pharmacies across the country, totaling over 70,000 pharmacy stores[43]. - The company operates over 10 online stores on platforms like Tmall, JD, and Pinduoduo, with a total fan base exceeding 5 million[43]. - The company ranks among the top three in China's medical dressing exports for several consecutive years[43]. Research and Development - The company has invested a total of ¥40,052.70 million from its IPO proceeds into fundraising projects, ensuring production capacity for its wound care and surgical infection control products[89]. - Research and development expenses surged by 409.70% to ¥259,712,735.22, up from ¥50,953,817.91 in the previous year[91]. - The company is focusing on enhancing its R&D capabilities, with several projects in clinical trials and product registration stages, including a dermal substitute and a skin cell enrichment device[135]. - The company has recognized the need for continuous improvement in its supply chain and quality management systems to mitigate product quality risks[167]. Acquisitions and Investments - The company acquired 70% equity of Suzhou Medis for a total transaction amount of CNY 104.16 million, with payments of CNY 62.50 million made in early 2019 and CNY 20.83 million during the reporting period[141]. - The company invested CNY 30 million to subscribe for additional capital of CNY 3.15 million in Stanger, acquiring a total of 60% equity after a cash purchase of CNY 45 million[141]. - The company acquired 65% equity of Hangzhou Xindong for CNY 1.95 million, completing the registration procedures during the reporting period[141]. - The company approved an investment of approximately CNY 360 million for the relocation and expansion of production lines for wound care products and surgical control products, with partial completion by the end of the reporting period[142]. Operational Efficiency - The company implemented lean manufacturing and smart factory initiatives to enhance operational efficiency and supply chain responsiveness[81]. - The company aims to strengthen its strategic partnerships with international and regional clients to further develop new product lines and increase market share[158]. - The company plans to gradually reduce shareholdings after the lock-up period, with annual reductions not exceeding 5% of the total share capital at the end of the previous year[191]. Future Outlook - The company aims to become a leading healthcare enterprise with a market value of over 100 billion RMB by focusing on "medical + health" sectors and enhancing digital operations and continuous R&D[154]. - The company plans to invest approximately RMB 12,000 million in a medical protective gear R&D and industrialization project, which is yet to commence[174]. - The company will enhance its digital marketing capabilities and improve operational efficiency through the integration of online and offline channels in the retail market[158]. - The company is actively seeking strategic acquisition opportunities in niche markets and key technologies globally[164].

2021 年第一季度报告 公司代码：603301 公司简称：振德医疗 振德医疗用品股份有限公司 2021 年第一季度报告 1 / 26 2021 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 26 2021 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人鲁建国、主管会计工作负责人金海萍及会计机构负责人（会计主管人员）马淑燕 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | --- | |-------------------------------------------------|------- ...

Financial Performance - Total assets increased to ¥6,357,397,507.64, up 138.17% from the previous year[18] - Net assets attributable to shareholders reached ¥3,564,436,804.63, reflecting a 162.33% increase year-over-year[18] - Operating revenue for the first three quarters was ¥8,116,660,488.11, a 531.52% increase compared to the same period last year[18] - Net profit attributable to shareholders was ¥2,097,753,320.69, representing a 2,105.56% increase year-over-year[18] - Cash flow from operating activities amounted to ¥2,673,731,914.25, a significant increase of 2,601.70% compared to the previous year[18] - Basic earnings per share increased to ¥10.53, up 2,048.98% from the previous year[18] - The weighted average return on equity rose to 85.93%, an increase of 77.70 percentage points compared to the previous year[18] - Total revenue for the period reached ¥8,116,660,488.11, a significant increase of 531.52% compared to ¥1,285,262,447.59 in the same period last year[31] - The company reported a net profit attributable to minority shareholders of ¥312,217,850.18, a substantial increase of 3387.62% compared to ¥8,952,168.26 in the same period last year[32] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2,077,402,698.86 RMB, representing a growth of 3,072.74% year-on-year[44] Sales and Market Performance - Sales of epidemic prevention protective products reached ¥6,107,694,520, a staggering increase of 11,599.15% year-over-year[21] - Domestic sales totaled ¥2,011,000,000, up 370.03% from the previous year, with epidemic prevention products contributing ¥1,461,000,000[21] - International sales were ¥6,098,000,000, a 612.14% increase year-over-year, with epidemic prevention products accounting for ¥4,646,000,000[21] - The company expects significant growth in net profit for the year 2020 compared to 2019, but there is uncertainty regarding the continued strong sales of pandemic-related protective products[44] Assets and Liabilities - The company's total liabilities decreased by 49.41% in bonds payable to ¥162,865,466.52 from ¥321,937,822.81, due to the conversion of some convertible bonds into shares[31] - Total liabilities as of September 30, 2020, were 2,426,256,281.71 RMB, up from 1,269,566,385.93 RMB at the end of 2019[55] - Total current liabilities were CNY 525,199,598.92, with short-term borrowings at CNY 292,487,185.54[98] Research and Development - The company is focusing on enhancing its research and development capabilities to drive innovation in new technologies[30] - Research and development expenses surged by 396.48% to ¥166,626,599.77 from ¥33,561,662.85, indicating a strong focus on innovation[31] - Research and development expenses in Q3 2020 amounted to ¥93,426,497.64, up from ¥11,017,612.97 in Q3 2019, reflecting an increase of approximately 747%[64] - The company reported a rise in research and development expenses due to increased investment in R&D during the reporting period[37] Strategic Initiatives - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[30] - There were no significant mergers or acquisitions reported during this period, indicating a focus on organic growth strategies[30] - The company aims to improve shareholder value through strategic initiatives and operational efficiencies in the upcoming quarters[30] - The company completed the acquisition of a 70% stake in Suzhou Medis Medical Sports Products Co., Ltd. for a total transaction amount of RMB 10.416 million[40] - The company has also invested RMB 30 million to acquire a 60% stake in Zhejiang Stanger Sports Protective Technology Co., Ltd. to enhance its product line in the sports rehabilitation sector[43] Cash Flow and Investments - The company reported cash inflows from investment activities totaling approximately ¥666.06 million, compared to ¥148.05 million in the previous year[81] - Cash outflows from investment activities amounted to approximately ¥1.94 billion, leading to a net cash flow from investment activities of approximately -¥1.27 billion[81] - Cash inflow from financing activities was approximately ¥1.05 billion, while cash outflows totaled approximately ¥1.07 billion, resulting in a net cash flow from financing activities of -¥27.65 million[82] - The company’s cash inflow from operating activities reflects a robust operational performance amidst challenging market conditions[86] Shareholder Information - The total number of shareholders at the end of the reporting period was 37,079, with the top ten shareholders holding a significant portion of the shares[26] - Zhejiang ZhenDe Holdings Co., Ltd. held 51.47% of the shares, making it the largest shareholder[28] - The second-largest shareholder, Shen Zhenfang, owned 4.39% of the shares, while the third-largest, Fang Shixiong, held 3.64%[28]